ライフサイエンスコーパス: vaccine therapy

1 between local radiation of tumor and active vaccine therapy.

2 mediated by T cells in the setting of cancer vaccine therapy.

3 ng tumor cells were implanted 14 days before vaccine therapy.

4 reast cancer cells is a potential target for vaccine therapy.

5 ls (DC) ex vivo as a model system for cancer vaccine therapy.

6 nant phenotype, would be an ideal target for vaccine therapy.

7 ccur within 3 months after completion of the vaccine therapy.

8 with tumors placed before the initiation of vaccine therapy.

9 develop vitiligo spontaneously or following vaccine therapy.

10 olecular adjuvants for specifically tailored vaccine therapies.

11 erial-derived small molecules as antigens in vaccine therapies.

12 oenvironment seems to impair the efficacy of vaccine therapies.

13 useful for the development of DC-based tumor vaccine therapies.

14 Provenge has brought new hope for anticancer vaccine therapies.

15 unosuppression toward potentiation of cancer vaccine therapies.

16 ciple and offers new practical solutions for vaccine therapy against cancer and other diseases in whi

17 This could advance vaccine therapy against cancer provided that precursor C

18 To enhance the effectiveness of DNA vaccine therapies and make possible the treatment of est

19 In the setting of lymphopenia, combined vaccine therapy and adoptive T-cell transfer fosters the

20 When vaccine therapy and local radiation of tumor were used i

21 GM-CSF and IL-2 vaccine therapy and pretreatment with gammaIFN represent

22 cluding 3 who had minimal disease at time of vaccine therapy and remain free of tumor with 16-30 mont

23 Forty-three patients chose vaccine therapy, and 11 patients chose postoperative obs

24 f infectious agents, their susceptibility to vaccine therapy, and human disease resistance.

25 immunization with single-agent or multiagent vaccine therapy appears equivalent.

26 targeted in more than 80 recent and ongoing vaccine therapy clinical trials involving QS-21 as a cri

27 cal tumor growth and an impaired response to vaccine therapy compared with CCR5 knockout (CCR5(-/-))

28 ases of the CNS may be adversely affected by vaccine therapies designed to boost autoreactive lymphoc

29 ll activation induced by a whole cancer cell vaccine therapy enhanced anticancer efficacy in a CD8(+)

30 Thus, HKL may be clinically effective in vaccine therapies for diseases such as allergy and asthm

31 ent important elements in the development of vaccine therapy for cancer.

32 An important issue for developing vaccine therapy for human malignancy is identifying adju

33 Vaccine therapy for prostate and breast cancer may have

34 ne response potentiation and dose-sparing in vaccine therapy given its exceedingly high level of pote

35 Cancer vaccine therapies have only achieved limited success whe

36 Nb-PM), working in a synergistic manner with vaccine therapy in an advanced mouse melanoma model.

37 st randomized, controlled trials of adjuvant vaccine therapy in human cancer reported to date.

38 Although VMO vaccine therapy in surgical adjuvant setting did not pro

39 Despite the efficacy of this approach for vaccine therapy, many questions remain regarding whether

40 Postoperative vaccine therapy may enhance IgG and IgM immune responses

41 In the setting of hepatectomy, multiagent vaccine therapy offers an advantage over single-agent th

42 uals enrolled in a trial of glycoprotein 160 vaccine therapy over the course of 3-5 years, lymphoprol

43 hypersensitivity (DTH) response to adjuvant vaccine therapy (P =.0001), and OS was significantly cor

44 ents revealed a significant OS advantage for vaccine therapy (P =.0009): 5-year OS was 39% for vaccin

45 during the past year with the approval of a vaccine therapy, second-line chemotherapy, and reported

46 se who are likely to benefit from a specific vaccine therapy; this approach may benefit future clinic

47 ey parameter relevant to the optimization of vaccine therapies through noninvasive MRI-based quantifi

48 adiation in combination with active specific vaccine therapy to elicit durable antitumor responses of

49 erical simulations of mixed chemo-immuno and vaccine therapy using both mouse and human parameters ar

50 However, neither radiation at this dose nor vaccine therapy was capable of inhibiting growth of 8-da

51 IR501 therapeutic vaccine therapy was safe and well tolerated, immunogenic

52 On multivariate analysis, vaccine therapy was the most significant prognostic vari

53 he 1,505 patients who were seen or who began vaccine therapy within 4 months after lymphadenectomy, a

54 Vaccine therapy would have the advantage of generating a